Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 558Carcinoma, Non-Small-Cell Lung 517Prostatic Neoplasms 335Colorectal Neoplasms 273Neoplasms 268Multiple Myeloma 267Leukemia, Myeloid, Acute 224Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 210Neoplasm Metastasis 205Carcinoma, Hepatocellular 197Melanoma 175Triple Negative Breast Neoplasms 173Pancreatic Neoplasms 171Recurrence 152Ovarian Neoplasms 152Lymphoma 141Glioblastoma 134Brain Neoplasms 133Sarcoma 130Carcinoma, Renal Cell 129Stomach Neoplasms 125Lymphoma, Large B-Cell, Diffuse 125Leukemia, Lymphocytic, Chronic, B-Cell 125Head and Neck Neoplasms 125Rectal Neoplasms 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Myelodysplastic Syndromes 103Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fibrocystic Breast Disease × 1 year × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡